A retrospective RWE-based RWS has identified the fixed-ratio combination insulin degludec/liraglutide for six months and are able to lower the incidence of diabetes-related complications and enhance quality-adjusted life expectancy while substantially reducing direct medical costs, compared to those of basal insulin, GLP-1 receptor agonists and oral medications[26]. The gene discussed is INS; the disease is diabetes mellitus.